The use of information for diabetes research and care: patient views in West London
In conclusion, wider sharing of health information may address some of the challenges diabetes care entails, although striking a balance between information fragmentation and sharing remains crucial to improve health, research and quality outcomes. Copyright © 2016 John Wiley & Sons. (Source: Practical Diabetes)
Source: Practical Diabetes - April 19, 2016 Category: Endocrinology Authors: A Zalin, C Papoutsi, K Shotliff, A Majeed, C Marston, J Reed Tags: Original article Source Type: research
Key insights into patients’ health record sharing
(Source: Practical Diabetes)
Source: Practical Diabetes - April 19, 2016 Category: Endocrinology Authors: Mary Hayes Tags: commentary Source Type: research
Pancreatitis, pancreatic cancer, and diabetes
(Source: Practical Diabetes)
Source: Practical Diabetes - March 31, 2016 Category: Endocrinology Authors: Rowan Hillson Tags: Leader Source Type: research
Alirocumab
(Source: Practical Diabetes)
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Fariha Naeem Tags: Drug notes Source Type: research
Analysing newly‐published diabetes audits: are care standards being achieved?
(Source: Practical Diabetes)
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Steve Chaplin Tags: Short report Source Type: research
Drug development and licensing in diabetes
Abstract
The drug development process is long and expensive. Regulatory approval is granted following assessment of efficacy and safety, and drugs intended for use in the treatment of type 2 diabetes are also required to demonstrate cardiovascular safety. Once marketing approval has been granted in the UK, an additional step is required prior to a drug's use: cost‐benefit assessment by the Scottish Medicines Consortium and by the National Institute for Health and Care Excellence. Empagliflozin, an SGLT‐2 inhibitor, has recently been granted marketing authorisation and approval for use in the UK. It will be used to illu...
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Andrea Llano, Miles Fisher, Gerry McKay Tags: Review Source Type: research
Inside the National Diabetes Audit – and beyond
(Source: Practical Diabetes)
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Mark Greener Tags: Policy profile Source Type: research
HHS in type 1 diabetes associated with medication overdose: can counter‐regulatory hormone suppression prevent diabetic ketoacidosis?
We present a case of hyperglycaemic hyperosmolar state in a patient with type 1 diabetes mellitus, associated with a mixed drug overdose including agents with documented CRH suppressive effects. We postulate that the drugs taken in overdose protected against diabetic ketoacidosis, and suggest further investigation of pharmacological therapies aimed at inhibiting CRH responses which may protect against this life‐threatening complication in patients with type 1 diabetes. Copyright © 2016 John Wiley & Sons. (Source: Practical Diabetes)
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: E Ghorani, ML Evans, D Simmons Tags: Case report Source Type: research
Diabetes in the shadow of daily life: factors that make diabetes a marginal problem
Abstract
The primary aim of this qualitative study, which was based on interviews with 24 patients with diabetes mellitus, was to identify factors that influence patients’ willingness and ability to adhere to prescribed medicines, to recommend lifestyle choices and to acquire a deeper understanding of the way these factors influence adherence. The starting point for the study was our belief that it may be of pivotal importance for health professionals to address patients’ life experiences, present life situations and cultural background, as well as their conceptions and attitudes, in order to understand why some patien...
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Anders Ågård, Vania Ranjbar, Susann Strang Tags: Original article Source Type: research
Sensor‐augmented pump therapy: review of new NICE diagnostic guidance
(Source: Practical Diabetes)
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Suchitra Raj, Ali Chakera Tags: NICE guidelines commentary Source Type: research
Diabetes and temperature
(Source: Practical Diabetes)
Source: Practical Diabetes - March 21, 2016 Category: Endocrinology Authors: Rowan Hillson Tags: Leader Source Type: research
Guidelines, ‘scandals’, and supporting clinicians in providing care for patients with diabetes
(Source: Practical Diabetes)
Source: Practical Diabetes - February 29, 2016 Category: Endocrinology Authors: Denis Pereira Gray, Eleanor White, Angus Thorne, Philip Evans Tags: Leader Source Type: research
Amitriptyline
(Source: Practical Diabetes)
Source: Practical Diabetes - January 28, 2016 Category: Endocrinology Authors: Kerri Devine Tags: Drug notes Source Type: research
The benefits of working together in diabetic foot care for the vulnerable patient
Abstract
The patient with a diabetic foot is extremely complex and vulnerable to tissue necrosis because three great pathologies come together in the diabetic foot: neuropathy, ischaemia and infection. As a result of neuropathy, the signs and symptoms of external physical insults and of infection may be minimal. Nevertheless, the pathology emanating from such insults and infection proceeds rapidly without the body being aware of them and the end‐stage of tissue death is quickly reached. Thus, the window of opportunity for intervention is limited and is often missed.
From a practical point of view, the diabetic foot can b...
Source: Practical Diabetes - January 28, 2016 Category: Endocrinology Authors: Michael Edmonds Tags: State of the art lecture Source Type: research
Vitiligo and lipohypertrophy surrounding insulin injection sites in a patient with type 1 diabetes
We present a case of vitiligo associated with lipohypertrophy in a patient with type 1 diabetes on Lantus and Novorapid subcutaneous insulin. The patient, a 55‐year‐old woman, was diagnosed with type 1 diabetes 53 years ago. Following 11 years using Novorapid and Lantus she developed lipohypertrophy at her injection sites with associated depigmentation of the skin. The depigmentation has recurred following changing injection sites.
We believe this is the first case of its kind to be reported in the literature and teaches a valuable lesson about the importance of examining injection sites. Copyright © 2016 John Wiley &...
Source: Practical Diabetes - January 28, 2016 Category: Endocrinology Authors: Karen Hedges, Ruth Poole Tags: Case report Source Type: research
